NUCLEAR MEDICINE THERAPY
Selective Internal Radiotherapy (SIRT)
SIRT is a form of internal radiotherapy used in the treatment of primary and secondary liver cancers.
Tiny radioactive resin microspheres are delivered into the main feeding artery to the liver, and they are floated upstream until they lodge. They then deliver a high local dose of radiation with the aim of causing
regression of the liver tumours. SIRT has been very successful in the treatment of liver cancers.
The treatment is performed under local anaesthetic and usually involves an overnight stay in hospital.
Lutetium (Lu-177) Radiopeptide Therapy
Lutetium labelled peptides are used in treating a variety of cancers. The radioactive Lu177 atom is bound to a short peptide molecule which directly attaches to receptors expressed on the surface of cancer cells. This therapy is particularly useful in treating advanced prostate cancer (Lu-177 PSMA) and neuroendocrine tumours (Lu-177 Octreotate). Diagnostic Nuclear Imaging has extensive experience in these therapies and is a leader in the field of Theranostics.
Radioactive Iodine Therapy
Radioactive iodine treatment for thyroid disease has been in clinical use since the late 1940's. It is a proven, safe, and simple method for treating thyroid overactivity. It is taken as an oral capsule, has no immediate side effects. The treatment is given on an outpatient basis. There are some radiation safety precautions required post treatment, but these are generally of a simple nature.
Samarium and Strontium Therapy
These treatments are given for palliation of secondary bone cancers, particularly from prostate and breast cancer. They are given as an injection into a vein, and are administered on an outpatient basis. These treatments are most useful in patients with pain related to bone secondaries, and will alleviate pain and reduce the need for strong narcotic pain killers.
This is a treatment for prostate cancer which has spread to bone. Unlike Strontium and Samarium which are given for the purposes of pain relief, Radium has an anti-tumour effect and results in tumour regression and prolonged survival. It is administered on an outpatient basis as a series of six injections, one month apart.